Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its lead product candidate is taletrectinib, an ROS1 inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer; Safusidenib, a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; NUV-868, a binding domain 2 selective, oral, small molecule bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.

Nuvation Bio Inc. Class A

In a report released on November 28, from Truist Financial maintained a Buy rating on Nuvation Bio. The company’s shares closed last Friday at $8.0...

Truist Financial Sticks to Their Buy Rating for Nuvation Bio (NUVB)

An announcement from Nuvation Bio ( ($NUVB) ) is now available. On November 26, 2025, Nuvation Bio announced the discontinuation of NUV-1511, a com...

Nuvation Bio Discontinues NUV-1511 Due to Efficacy Issues

TD Cowen analyst Yaron Werber reiterated a Buy rating on Nuvation Bio on November 18. The company’s shares closed yesterday at $4.80. According to ...

Nuvation Bio (NUVB) Receives a Buy from TD Cowen

Nuvation Bio ( ($NUVB) ) has provided an update. On November 8, 2025, Nuvation Bio announced positive results from a Phase 2 study of safusidenib i...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NUVB	$8.43	+1.93%	6.07M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NUVB	$8.43	+1.9%	6.07M
3
4
5
6

NUVB

NUVB

Dividend Overview

Get Nuvation Bio Inc. Class A Data in Excel

Get Nuvation Bio Inc. Class A Data in Excel